Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of HL-1186 for diabetic peripheral neuropathic pain
ChiCTR2500109625Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HL-1186 in diabetic polyneuropathy (DPN) (3 arms), sponsored by Peking University First Hospital. Primary endpoint: Change in average daily pain score from baseline after 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
HL-1186
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on ChiCTR2500109625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109625.